$FEED

ENvue Medical (NASDAQ: FEED) said Zeev Rotstein, M.D. was appointed Chairman of the Board, replacing David Johnson, who and Nino Pionati are departing. ENvue also added Zvi Joseph and Lior Buchman as directors. The company cited Joseph’s AI governance background at Amdocs and Buchman’s $320 million in executed financings and M&A.

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001326706 0001326706 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

ENvue Medical (NASDAQ: FEED) said it developed and demonstrated a prototype of ENvue Drive, a robotic-assisted, AI-integrated tool within its electromagnetic navigation platform. The company integrated its Ask Oscar AI navigation software with robotic tube advancement in a simulated enteral procedure. ENvue Drive is investigational and not FDA submitted or cleared.

ENvue Medical (NASDAQ: FEED) said it developed and demonstrated a first prototype of ENvue Drive, a robotic-assisted, AI-integrated tool within its electromagnetic navigation platform. The prototype combined Ask Oscar AI navigation with robotic tube advancement in a simulated bedside enteral procedure. ENvue Drive is investigational and not FDA-cleared.

Glibert Christian Michael sold 210,000 shares of ENvue Medical, Inc. (FEED) at $0.69 ($0.14M total) on 2026-06-22.

ENvue Medical (NASDAQ: FEED) has registered the resale of up to 6,000,768 shares of common stock, which are issuable upon the conversion of Series H Convertible Preferred Stock. The company will not receive any proceeds from these resales, as they are for the benefit of a selling stockholder. This registration could lead to significant dilution, representing approximately 53.4% of outstanding shares, and may impact the company's stock price and compliance with Nasdaq listing requirements.

ENvue Medical has renewed a three-year purchasing agreement with a Group Purchasing Organization representing one of the largest non-profit health systems in the U.S., encompassing over 90 hospitals across 17 states. This renewal simplifies the procurement process for its ENvue Navigation Platform, allowing participating hospitals to adopt the technology without individual facility-level approvals. The agreement aims to increase utilization and expand ENvue's installed base within the extensive network through 2028.

ENvue Medical has renewed a three-year purchasing agreement with a Group Purchasing Organization for a major U.S. health system, covering over 90 hospitals across 17 states. This agreement streamlines access to ENvue's Navigation Platform, removing the need for individual facility approvals and providing a strong commercial foundation for the company. The renewal signifies confidence in ENvue's technology and is expected to drive broader utilization within the network.

ENvue Medical has secured a multi-year renewal of its purchasing agreement with a major U.S. nonprofit hospital system, providing continued access to its ENvue Navigation Platform through 2028. This agreement streamlines procurement for over 90 hospitals across 17 states, removing the need for individual facility reviews and potentially accelerating adoption. The ENvue Navigation Platform is an FDA 510(k) cleared system designed to assist clinicians in placing feeding tubes with real-time bedside visualization.

ENvue Medical (FEED) has received a Notice of Allowance from the USPTO for a patent integrating electromagnetic guidance with direct internal visualization for feeding tubes. This development is expected to expand the company's intellectual property, enhance its competitive edge in the enteral access market, and bolster its next-generation product development capabilities. While the patent is a positive step, ENvue Medical faces financial challenges, including negative operating margins and an Altman Z-Score indicating financial distress.